3D molecular descriptors important for clinical success

Journal of Chemical Information and Modeling

Volumn 53, Issue 2, 2013, Pages 327-342

  Kombo, David C ^a   Tallapragada, Kartik ^a   Jain, Rachit ^b   Chewning, Joseph ^a   Mazurov, Anatoly A ^a   Speake, Jason D ^a   Hauser, Terry A ^a   Toler, Steve ^a  

^a TARGACEPT INC   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCE; DIGITAL STORAGE; LIGANDS;

AROMATIC RINGS; AS FRACTIONS; CARBON ATOMS; CLINICAL DRUGS; CLINICAL TRIAL; MOLECULAR DESCRIPTORS; RADIUS OF GYRATION; SHADOW INDICES;

PHYSICOCHEMICAL PROPERTIES;

DRUG; LIGAND; PROTEIN;

ANIMAL; ARTICLE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DATABASE; DRUG DEVELOPMENT; HUMAN; METABOLISM; METHODOLOGY; PHARMACOLOGY; SOLUBILITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; PROTEINS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874436407     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci300445e     Document Type: Article

References (65)

1. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: Increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756
2. Mc Govern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechansim underlying promiscuous inhibitors from virtual and high-throughut screening J. Med.Chem. 2002, 45, 1712-1722
3. Mc Govern, S. L.; Shoichet, B. K. Kinase inhibitors: Not just for kinases anymore J. Med. Chem. 2003, 46, 1478-1483
4. Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K. High-throughput assays for promiscuous inhibitors Nat. Chem. Biol. 2005, 1, 146-148
5. Feng, B. Y.; Shoichet, B. K. Synergy and antagonism of promiscuous inhibition in multiple-compound librairies J. Med. Chem. 2006, 49, 2151-2154
6. Metz, J. T.; Huth, J. R.; Hajduk, P. J. Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups J. Comput.-Aided. Mol. Des. 2007, 21, 139-144
7. Huth, J. R.; Song, D.; Mendoza, R. R.; Black-Schaefer, C. L.; Mack, J. C.; Dorwin, S. A.; Ladror, U. S.; Severin, J. M.; Walter, K. A.; Bartley, D. M.; Hajduk, P. Toxicological evaluation of thiol reactive compounds identified using a La assay to detect reactive molecules by nuclear magnetic resonance Chem. Res. Toxicol. 2007, 20, 1752-1759
8. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (Pains) from screening librairies and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719-2740
9. Meanwell, N. A. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 2011, 24, 1420-1456
10. Ehrlich, P. The theory and practice of chemotherapy Folia Serol. 1911, 7, 697-714
11. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
12. Bhal, S. K.; Kassam, K.; Peirson, I. G.; Pearl, G. M. The rule of five revisited: Applying Log D in place of Log P in drug-likeness filters Mol. Pharm. 2007, 4, 556-560
13. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623
14. Ritchie, T. J.; Macdonald, S. J. F. The impact of aromatic rings count on compound developability-Are too many aromatic rings a liability in drug design? Drug Discovery Today 2009, 14, 1011-1020
15. Clemons, P. A.; Bodycombe, N. E.; Carrinski, H. A.; Wilson, J. A.; Shamji, A. F.; Wagner, B. K.; Koeler, A. N.; Schreiber, S. L. Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 18787-18792
16. Clemons, P. A.; Wilson, J. A.; Dančik, V.; Muller, S.; Carrinski, H. A.; Wagner, B. K.; Koehler, A. N.; Schreiber, S. L. Quantifying structure and performance diverisity for sets of small molecules comprising small-molecule screening collections Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 6817-6822
17. Philip, N. S.; Carpenter, L. L.; Tyrka, A. R.; Price, L. H. Nicotinic acetylcholine receptors and depression: A review of the preclinical and clinical literature Psychopharmacology (Berl.) 2011, 212, 1-12
18. Taly, A.; Corringer, P. J.; Guedin, D.; Lestage, P.; Changeux, J. P. Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system Nat. Rev. Drug Discovery 2009, 8, 733-750
19. Lippiello, P. M.; Bencherif, M.; Hauser, T. A.; Jordan, K. G.; Letchworth, S. R.; Mazurov, A. A. Nicotinic receptors as targets for therapeutic discovery Expert Opin. Drug Discovery 2007, 2, 1185-203
20. Romanelli, M. N.; Gratteri, L.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. Central nicotinic receptors: Structure, function, ligands, and therapeutic potential Chem. Med. Chem. 2007, 2, 2-24
21. Breining, S. R. Recent developments in the synthesis of nicotinic acetylcholine receptor ligands Curr. Top. Med. Chem. 2004, 4, 609-629
22. Mazurov, A. A.; Hauser, T. A.; Miller, C. H. Selective α7 nicotinic acetylcholine receptor ligands Curr. Med. Chem. 2006, 13, 1567-1584
23. Bencherif, M.; Schmitt, J. D. Targeting neuronal nicotinic receptors: A path to new therapies Current Drug Targets CNS Neurol. Disord. 2002, 1, 349-357
24. Peters, J.-U.; Schnider, P.; Mattei, P.; Kansy, M. Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds ChemMedChem 2009, 4, 680-686
25. Peters, J. U.; Hert, J.; Bissantz, C.; Hillebrecht, A.; Gerebtzoff, G.; Bendels, S.; Tillier, F.; Migeon, J.; Fischer, H.; Guba, W.; Kansy, M. Can we discover pharmacological promiscuity early in the drug discovery process? Drug Discovery Today 2012, 17, 325-335
26. Whitebread, S.; Hamon, J.; Bojanic, D.; Urban, L. In vitro safety pharmacology profiling: An essential tool for successful drug development Drug Discov. Today 2005, 10, 1421-1433
27. Hamon, J.; Whitebread, S.; Techer-Etienne, V.; Le Coq, H.; Azzaoui, K.; Urban, L. In vitro safety pharmacology profiling: What else beyond hERG? Future Med. Chem. 2009, 1, 645-665
28. MDDR; Accelrys, Inc.: San Diego, CA, 2006.
29. Mazurov, A.; Miao, L.; Klucik, J. Heteroaryl-Substituted Diazabicycloalkanes: Methods for Its Preparation and Use Thereof. U.S. Patent 7732607, 2010.
30. Mazurov, A.; Klucik, J.; Miao, L.; Phillips, T. Y.; Seamans, A.; Schmitt, J. D.; Hauser, T. A.; Johnson, R. T.; Miller, C. H. 2-(Arylmethyl)-3- substituted quinuclidines as selective α7 nicotinic receptor ligands Bioorg. Med. Chem. Lett. 2005, 15, 2073-2078
31. Bencherif, M.; Jordan, C.; Hauser, T.; Toler, S. M.; Letchworth, S. R.; Kombo, D. C. Treatment with alpha-7 Selective Ligands. WO Patent 2010/56622, 2010.
32. Breining, S. R.; Mazurov, A.; Miller, C. H.; Phillips, T. Y.; Miao, L.; Bhatti, B. S.; Hawkins, G. D. Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders. U.S. Patent 7897611, 2011.
33. Caldwell, W. S.; Dull, G. M.; Bhatti, B. S.; Hadimani, S. B.; Park, H.; Wagner, J. M.; Crooks, P. A.; Lippiello, P. M.; Bencherif, M. Hydroxybenzoate Salts of Metanicotine Compouinds. U.S. Patent 7459469, 2008.
34. Breining, S. R.; Mazurov, A.; Miller, C. H.; Phillips, T. Y.; Miao, L.; Bhatti, B. S.; Hawkins, G. D. Pharmaceutical compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders. U.S Patent 7402592, 2008.
35. Dull, G. M.; Munoz, J. A.; Moore, J. R.; Genus, J. Hydroxybenzoate Salts of Metanicotine Compounds. U.S Patent 7459469, 2008.
36. Bhatti, B. S.; Gatto, G. J.; Klucik, J. The Use of N-aryl Diazaspirocyclic Compounds in the Treatment of Addiction. European Patent 1784184, 2007.
37. Strachan, J. P.; Cuthberson, T. J.; Wirth, D. D.; Dull, G. M.; Letchworth, S. R.; Jordan, K. G.; Kombo, D. C. Salt forms of 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1.] Heptane WO Patent 2012/125518, 2012.
38. Gopalakrishnan, M.; Honore, M., P.; Lee, C.; Malysz, J.; Ji, J.; Li, T.; Schrimpf, M., R.; Sippy, K. B.; Anderson, D. J. Pharmaceutical Compositions and Their Methods of Use. European Patent 2226074, 2011.
39. Bhatti, B. S.; Schmitt, J. D.; Clark, T. J.; Miller, C. H. Pharmaceutical Compositions and Methods for Use. U.S. Patent 6579878, 2003.
40. Crooks, P. A.; Deo, N. M. Pharmaceutical Compositions and Methods for Use. U.S. Patent 6211372, 2001.
41. Coe, J. W.; Brooks, P. R.; Vetelino, M. G.; Wirtz, M. C.; Arnold, E. P.; Huang, J.; Sands, S. B.; Davis, T. I.; Lebel, L. A.; Fox, C. B.; Shrikhande, A. Varenicline: An α4β2 nicotinic receptor partial agonist for smoking cessation J. Med. Chem. 2005, 48, 3474-3477
42. Bhatti, B. S.; Strachan, J.-P.; Breining, S. R.; Miller, C. H.; Tahiri, P.; Crooks, P. A.; Deo, N.; Day, C. S.; Caldwell, W. S. Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2] octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor ligands J. Org. Chem. 2008, 73, 3497-3507
43. Mazurov, A.; Miao, L.; Xiao, Y.; Yohannes, D.; Akireddy, S. R.; Breining, S. R.; Kombo, D.; Murthy, V. S. Derivatives of Oxabispidine as Neuronal Nicotinic Acetylcholine Receptor Ligands. European Patent 2356125, 2011.
44. Mazurov, A. A.; Miao, L.; Bhatti, B. S.; Strachan, J. P.; Akireddy, S.; Murthy, S.; Kombo, D.; Xiao, Y. D.; Hammond, P.; Zhang, J.; Hauser, T. A.; Jordan, K. G.; Miller, C. H.; Speake, J. D.; Gatto, G. J.; Yohannes, D. Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders J. Med. Chem. 2012, 55, 9181-9194
45. Mazurov, A. A.; Kombo, D. C.; Hauser, T. A.; Miao, L.; Dull, G.; Genus, G. F.; Fedorov, N. B.; Benson, L.; Sidach, S.; Xiao, Y.; Hammond, P. S.; James, J. W.; Miller, C. H.; Yohannes, D. Discovery of (2S,3R)-N-[2-(Pyridin-3- ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders J. Med. Chem. 2012, 55, 9793-9809
46. Hahn, M. Receptor surface models. 1. Definition and construction J. Med. Chem. 1995, 38, 2080-2090
47. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: A comprehensive resource for "omics" research on drugs Nucleic Acids Res. 2011, 39 (Database issue) D1035-41
48. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: A knowledgebase for drugs, drug actions and drug targets Nucleic Acids Res. 2008, 36 (Database issue) D901-906
49. Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: A comprehensive resource for in silico drug discovery and exploration Nucleic Acids Res. 2006, 1 (Database issue) D668-672
50. Hou, T. J.; Xia, K.; Zhang, W.; Xu, X. J. ADME evaluation in drug discovery. 4. Prediction of aqueous solubility based on atom contribution approach J. Chem. Inf. Comp. Sci. 2003, 44, 266-275
51. Field, A. Discovering Statistics Using SPSS (Introducing Statistical Method), 3 rd ed.; Sage Publications Ltd: Thousand Oaks, CA, 2009.
52. Storey, J. D. A direct approach to false discovery rates J. R. Stat. Soc. B 2002, 64, 479-498
53. Azzaoui, K.; Hamon, J.; Faller, B.; Whitebread, S.; Jacoby, E.; Bender, A.; Jenkins, J. L.; Urban, L. Modeling promiscuity based on in vitro safety pharmacology profiling data ChemMedChem 2007, 2, 874-880
54. Medina-Franco, J. L.; Maggiora, G. M.; Giulianotti, M. A.; Pinilla, C.; Houghten, R. A. A similarity-based data-fusion approach to the visual characterization and comparison of compound databases Chem. Biol. Drug Des. 2007, 70, 393-412
55. Akella, L. B.; DeCaprio, D. Cheminformatics approaches to analyze diversity in compound screening librairies Curr Opin. Chem. Biol. 2010, 14, 325-330
56. Halgren, T. A.; MMFF, V. I. MMFF94s option for energy minimization studies J. Comput. Chem. 1999, 20, 720-729
57. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136
58. Rohrbaugh, R. H.; Jurs, P. C. Descriptions of molecular shape applied in studies of structure/activity and structure/property relationships Anal. Chim. Acta 1987, 199, 99-109
59. Yera, E. R.; Cleves, A. E.; Jain, A. N. Chemical structural novelty: On-targets and off-targets J. Med. Chem. 2011, 54, 6771-6785
60. Nettles, J. H.; Jenkins, J. L.; Bender, A.; Deng, Z.; Davies, J. W.; Glick, M. Bridging chemical and biological space: "Target fishing" using 2D and 3D molecular descriptors J. Med. Chem. 2006, 49, 6802-6810
61. Perez-Nueno, V. I.; Venkatraman, V.; Mavridis, L.; Ritchie, D. W. Predicting drug polypharmacology using novel surface property similarity-based approach J. Med. Chem. 2011, 3 (Suppl. 1) O19
62. Hampton, T. Promiscuous anticancer drugs that hit multiple targets may thwart resistance J. Am. Med Soc. 2004, 292, 419-422
63. Fabian, M. A.; Biggs, W. H. I., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lélias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336
64. Atwell, S.; Adams, J.; Badger, J.; Buchanan, M. D.; Feil, I. K.; Froning, K. J.; Gao, X.; Hendle, J.; Keegan, K.; Leon, B. C.; Müller-Dieckmann, H. J.; Nienaber, V. L.; Noland, B. W.; Post, K.; Rajashankar, K. R.; Ramos, A.; Russel, M.; Burley, S. K.; Buchanan, S. G. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase J. Biol. Chem. 2004, 279, 55827-55832
65. Kung, C.; Kenski, D. M.; Dickerson, S. H.; Howson, R. W.; Kuyper, L. F.; Madhani, H. D.; Shokat, K. M. Chemical genomic profiling to identify intracellular targets to a multiplex kinase inhibitor Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3587-3592